BRPI0416032A - excipientes em veìculos de distribuição de fármacos - Google Patents

excipientes em veìculos de distribuição de fármacos

Info

Publication number
BRPI0416032A
BRPI0416032A BRPI0416032-0A BRPI0416032A BRPI0416032A BR PI0416032 A BRPI0416032 A BR PI0416032A BR PI0416032 A BRPI0416032 A BR PI0416032A BR PI0416032 A BRPI0416032 A BR PI0416032A
Authority
BR
Brazil
Prior art keywords
excipients
polymers
drug delivery
delivery vehicles
gel compositions
Prior art date
Application number
BRPI0416032-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Guohua Chen
David T Priebe
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0416032A publication Critical patent/BRPI0416032A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00Bandages or dressings; Absorbent pads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0416032-0A 2003-11-14 2004-11-12 excipientes em veìculos de distribuição de fármacos BRPI0416032A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51997203P 2003-11-14 2003-11-14
US10/985,116 US20050281879A1 (en) 2003-11-14 2004-11-10 Excipients in drug delivery vehicles
PCT/US2004/037606 WO2005048989A1 (en) 2003-11-14 2004-11-12 Excipients in drug delivery vehicles

Publications (1)

Publication Number Publication Date
BRPI0416032A true BRPI0416032A (pt) 2007-01-02

Family

ID=34623114

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416032-0A BRPI0416032A (pt) 2003-11-14 2004-11-12 excipientes em veìculos de distribuição de fármacos

Country Status (14)

Country Link
US (1) US20050281879A1 (https=)
EP (1) EP1691785A4 (https=)
JP (1) JP2007511516A (https=)
KR (1) KR20060125748A (https=)
AR (1) AR046842A1 (https=)
AU (2) AU2004291077A1 (https=)
BR (1) BRPI0416032A (https=)
CA (1) CA2545913C (https=)
IL (1) IL175601A0 (https=)
MX (1) MXPA06005464A (https=)
NO (1) NO20062781L (https=)
PE (1) PE20050494A1 (https=)
TW (1) TW200524631A (https=)
WO (1) WO2005048989A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2355385C2 (ru) * 2002-11-06 2009-05-20 Алза Корпорейшн Композиции пролонгированного действия с контролируемым высвобождением
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602006020568D1 (de) * 2005-07-02 2011-04-21 Arecor Ltd Stabile wässrige systeme mit proteinen
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2013202598B2 (en) * 2005-09-30 2016-06-09 Durect Corporation Sustained release small molecule drug formulation
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US7261742B2 (en) 2005-10-13 2007-08-28 S.C. Johnson & Son, Inc. Method of deodorizing a textile
US7407922B2 (en) 2005-10-13 2008-08-05 S.C. Johnson & Son, Inc. Deodorizing compositions
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
EP2359808B1 (en) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Osmotic delivery systems and piston assemblies
WO2008133908A2 (en) 2007-04-23 2008-11-06 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2167039B1 (en) 2007-05-18 2016-09-28 Durect Corporation Improved depot formulations
ES2562878T3 (es) 2007-05-25 2016-03-08 Indivior Uk Limited Formulaciones de liberación sostenida de compuestos de risperidona
WO2009110939A2 (en) * 2007-12-10 2009-09-11 Massachusetts Institute Of Technology Drug delivery system for pharmaceuticals and radiation
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US8956642B2 (en) * 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US20100016808A1 (en) * 2008-07-17 2010-01-21 Bioform Medical, Inc. Thin-Walled Delivery System
ES2344674B1 (es) * 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2013142996A1 (en) * 2012-03-30 2013-10-03 The Royal Institution For The Advancement Of Learning/Mcgill University Magnesium phosphate gels
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
EA033537B1 (ru) 2013-03-11 2019-10-31 Durect Corp Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CA3015557C (en) 2014-11-07 2019-07-16 Indivior Uk Limited The use of sustained-release buprenorphine formulations for the treatment of pain or opioid use disorders
US11090296B2 (en) * 2015-03-18 2021-08-17 Santen Pharmaceutical Co., Ltd. Sustained-release pharmaceutical composition
RU2730996C2 (ru) 2015-06-03 2020-08-26 Интарсия Терапьютикс, Инк. Системы установки и извлечения имплантата
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
CN107708738B (zh) * 2015-07-01 2022-03-25 参天制药株式会社 含有柠檬酸酯的贮库制剂
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN105295310A (zh) * 2015-11-11 2016-02-03 苏州国泰科技发展有限公司 一种绿色环保型增塑剂
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
JP7286542B2 (ja) 2017-01-03 2023-06-05 インターシア セラピューティクス,インコーポレイティド Glp-1受容体アゴニストの持続的投与及び薬物の同時投与を含む方法
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN115666621A (zh) 2020-01-13 2023-01-31 度勒科特公司 具有减少的杂质的持续释放药物递送系统及相关方法
CA3203561A1 (en) 2021-01-12 2022-07-21 Adrian Neil Verity Sustained release drug delivery systems and related methods

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US630200A (en) * 1899-03-13 1899-08-01 Draper Co Warp-stop-motion mechanism.
US4443340A (en) * 1981-10-09 1984-04-17 Betz Laboratories, Inc. Control of iron induced fouling in water systems
US4985404A (en) * 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4853218A (en) * 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5912015A (en) * 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
DE69311538D1 (de) * 1992-03-12 1997-07-17 Alkermes Inc Acth enthaltende mikrokugeln mit gesteuerter abgabe
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) * 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5242910A (en) * 1992-10-13 1993-09-07 The Procter & Gamble Company Sustained release compositions for treating periodontal disease
CA2150803C (en) * 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
JP4259610B2 (ja) * 1994-04-08 2009-04-30 キューエルティー・ユーエスエイ・インコーポレーテッド 液体デリバリー組成物
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6184227B1 (en) * 1995-07-21 2001-02-06 Savvipharm Inc. Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
US5801012A (en) * 1996-09-17 1998-09-01 Northwestern University Methods and compositions for generating angiostatin
JP4642946B2 (ja) * 1996-12-20 2011-03-02 アルザ コーポレイション ゲル組成物および方法
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
JP3077635B2 (ja) * 1997-06-20 2000-08-14 日本電気株式会社 高速無線アクセス装置
JP2002532210A (ja) * 1998-12-18 2002-10-02 アンジオソニックス インコーポレイテッド 超音波により癌および他の細胞増殖性疾病を阻止および治療する方法
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
CA2446060A1 (en) * 2001-05-07 2002-11-14 Corium International Compositions and delivery systems for administration of a local anesthetic agent
JP5170935B2 (ja) * 2001-11-14 2013-03-27 デュレクト コーポレーション 注入可能なデポー組成物
EP1446101B1 (en) * 2001-11-14 2011-03-23 Durect Corporation Catheter injectable depot compositions and uses thereof
DE60239952D1 (de) * 2001-11-14 2011-06-16 Durect Corp Injizierbare depotzusammensetzungen und deren verwendung
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
US20050106214A1 (en) * 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles

Also Published As

Publication number Publication date
MXPA06005464A (es) 2006-08-11
WO2005048989A1 (en) 2005-06-02
AU2004291077A1 (en) 2005-06-02
CA2545913A1 (en) 2005-06-02
US20050281879A1 (en) 2005-12-22
AU2011201972B2 (en) 2013-06-13
IL175601A0 (en) 2006-09-05
JP2007511516A (ja) 2007-05-10
TW200524631A (en) 2005-08-01
EP1691785A1 (en) 2006-08-23
AR046842A1 (es) 2005-12-28
KR20060125748A (ko) 2006-12-06
CA2545913C (en) 2013-12-31
AU2011201972A1 (en) 2011-05-19
NO20062781L (no) 2006-08-14
PE20050494A1 (es) 2005-08-24
EP1691785A4 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
BRPI0416032A (pt) excipientes em veìculos de distribuição de fármacos
BRPI0416590A (pt) excipientes em veìculos de distribuição de fármacos
BR0315304A (pt) Formulações com depósito para liberação controlada
BRPI0410956A (pt) pelìculas com base em óxido de polietileno e sistemas de liberação de droga feitos delas
BR9915235A (pt) ácidos hialurÈnicos reticulados e usos médicos dos mesmos
BR0313539A (pt) Composições depósito de polìmero multimodais injetáveis e seus usos
BR9815570A (pt) Composto, processo de preparação dos compostos, utilização de pelo menos um composto, composição cosmética ou farmacêutica e utilização de pelos menos um polìmero
IT1317358B1 (it) Derivati cross-linkati dell'acido ialuronico.
DE60316291D1 (de) Esterderivate von hyaluronsäure zur herstellung von hydrogelmaterialien durch photohärtung
ATE349202T1 (de) Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage
BR0113663A (pt) Composições de pelìcula de pectina
BRPI0418309B8 (pt) "géis coesos de hialuronado e/ou hilano reticulados, processo para a preparação dos mesmos, bem como composições e dispositivos compreendendo os referidos géis".
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
BRPI0414907A (pt) formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
MXPA05013290A (es) Composiciones oftalmicas que contienen una combinacion sinergistica de dos polimeros.
BR0313428A (pt) Composições farmacêuticas de drogas semi-ordenados e polìmeros
BR0309340A (pt) Materiais, sua preparação e uso
BRPI0411367A (pt) composições oftálmicas contendo uma combinação sinergìstica de três polìmeros
WO2007131193A3 (en) Main chain acid-degradable polymers for the delivery of bioactive materials
SI1608346T1 (sl) Spojine za sproščanje zdravilnih učinkovin na osnovi alfa-hidroksi kislinskih estrov in postopki njihove uporabe
BR0011554A (pt) Composições e métodos para usar intensificadores de espuma poliméricos
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
DOP2003000621A (es) Inhibidores triariloxiariloxipirimidin-2,4,6-triona de metaloproteinasa
AU2003256882A1 (en) Methods of drug delivery using sulphated chitinous polymers
ATE359800T1 (de) Pharmazeutische zusammensetzung mit einem zink/hyaluronat-komplex zur behandlung von multipler sklerose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.